About the book
Advocates of rapid access to medicines and critics fearful of inadequate testing both argue that globalization will supersede national medical practices and result in the easy transfer of pharmaceuticals around the world. In Pharmacopolitics, Arthur Daemmrich challenges their assumptions by comparing drug laws, clinical trials, and systems for monitoring adverse reactions in the United States and Germany, two countries with similarly advanced systems for medical research, testing, and patient care. Daemmrich proposes that divergent “therapeutic cultures” — the interrelationships among governments, patients, the medical profession, and the pharmaceutical industry — underlie national differences and explain variations in pharmaceutical markets and medical care.
Daemmrich carries the United States–Germany comparison from 1950 to the present through case studies of Terramycin (an antibiotic), thalidomide (a sedative), propranolol (a heart medication), interleukin-2 (a cancer therapy), and indinavir (an AIDS drug). He points to different political constructions of “the patient” in the United States and Germany to clarify important differences in government policies and in the distribution of power among key social actors. Daemmrich advises that international regulatory harmonization and globalization in medicine must retain flexibility for social and political variation between countries, even as they achieve technical standardization.
Editions of Pharmacopolitics
- Hardcover
- ISBN 9780807828441
- Paperback
- ISBN 9780807872413
- EBook
- ISBN 9780807863398
- PDF
- ISBN 9798890878397
Read an Excerpt
Advocates of rapid access to medicines and critics fearful of inadequate testing both argue that globalization will supersede national medical practices and result in the easy transfer of pharmaceuticals around the world. In Pharmacopolitics, Arthur Daemmrich challenges their assumptions by comparing drug laws, clinical trials, and systems for monitoring adverse reactions in the United States and Germany, two countries with similarly advanced systems for medical research, testing, and patient care. Daemmrich proposes that divergent “therapeutic cultures” — the interrelationships among governments, patients, the medical profession, and the pharmaceutical industry — underlie national differences and explain variations in pharmaceutical markets and medical care.
Daemmrich carries the United States–Germany comparison from 1950 to the present through case studies of Terramycin (an antibiotic), thalidomide (a sedative), propranolol (a heart medication), interleukin-2 (a cancer therapy), and indinavir (an AIDS drug). He points to different political constructions of “the patient” in the United States and Germany to clarify important differences in government policies and in the distribution of power among key social actors. Daemmrich advises that international regulatory harmonization and globalization in medicine must retain flexibility for social and political variation between countries, even as they achieve technical standardization.
Frequently Asked Questions
What is Pharmacopolitics about?
Advocates of rapid access to medicines and critics fearful of inadequate testing both argue that globalization will supersede national medical practices and result in the easy transfer of pharmaceuticals around the world. In Pharmacopolitics, Arthur Daemmrich challenges their assumptions by comparing drug laws, clinical trials, and systems for monitoring adverse reactions in the United States and Germany, two countries with similarly advanced systems for medical research, testing, and patient care. Daemmrich proposes that divergent “therapeutic cultures” — the interrelationships among governments, patients, the medical profession, and the pharmaceutical industry — underlie national differences and explain variations in pharmaceutical markets and medical care.
Daemmrich carries the United States–Germany comparison from 1950 to the present through case studies of Terramycin (an antibiotic), thalidomide (a sedative), propranolol (a heart medication), interleukin-2 (a cancer therapy), and indinavir (an AIDS drug). He points to different political constructions of “the patient” in the United States and Germany to clarify important differences in government policies and in the distribution of power among key social actors. Daemmrich advises that international regulatory harmonization and globalization in medicine must retain flexibility for social and political variation between countries, even as they achieve technical standardization.
What core themes, tropes, or subjects are explored in Pharmacopolitics?
Reference, Information and Interdisciplinary subjects > Interdisciplinary studies > Globalization
Where can I read a sample of Pharmacopolitics?
You can read an official preview of the few pages here https://www.book2look.com/book/9780807828441
How long is Pharmacopolitics and how many pages does it have?
Pharmacopolitics has 224 page(s)
Is Pharmacopolitics part of a series, and can it be read as a standalone?
Yes it is a part of series Studies in Social Medicine
Who is/are the Author/s of the book Pharmacopolitics?
Arthur A. Daemmrich
What are the ISBN numbers for the physical and digital editions?
Pharmacopolitics is available as hardcover(ISBN 9780807828441) and paperback(ISBN 9780807872413) and ebook(ISBN 9780807863398) and pdf(ISBN 9798890878397)
Where can I buy Pharmacopolitics online or support local independent bookshops?
You can buy Pharmacopolitics from below
Where can I buy Pharmacopolitics?